GHK-Cu: Copper Peptide and Research Overview 2026

Note upfront: This article is for information only and is not a recommendation for use. Cosmetic preparations with GHK-Cu have been on the market for decades. Injectable, systemic forms are not approved as drugs in the EU or the US and are sold as “research chemicals”. Intake, dose and therapy should be clarified with a doctor. For unapproved substances, Lab2go explicitly gives no recommendation for use.

TL;DR: GHK-Cu is an endogenous tripeptide (glycine-histidine-lysine) bound to copper, described in 1973 by Loren Pickart. According to the available data, plasma concentration drops from about 200 ng/ml at age 20 to about 80 ng/ml at age 60. For cosmetic preparations on the skin there are small studies on wrinkles, skin elasticity and wound healing. For injected forms there is little human data and no approval.

What GHK-Cu Is

GHK-Cu refers to the complex of the tripeptide glycyl-L-histidyl-L-lysine and a bound copper(II) ion. Loren Pickart described the molecule in 1973 in human plasma while investigating why blood from older people regenerated liver cells less well than blood from young people. The difference was GHK.

Endogenous plasma concentration follows an age trend:

• Age 20: about 200 ng/ml
• Age 40: about 120 ng/ml
• Age 60: about 80 ng/ml

This decline correlates with reduced healing and regenerative capacity. GHK-Cu is therefore not a synthetic foreign molecule like many other peptides, but a natural body substance whose concentration drops with age. A correlation does not show, however, that external supply compensates for anything.

The molecule also appears in saliva and urine but is primarily distributed through plasma. Its key biological role: to transport copper as a catalyst to target tissues without letting free copper cause oxidative stress.

Mechanisms Overview

Studies examine GHK-Cu at several levels. The mechanisms are described mainly in cell culture and animal models, and for skin partly also in small human studies.

The Pickart and Margolina (2015) paper in Biomed Research International is the most cited mechanistic contribution: in gene expression data GHK modulates about 4,000 genes and shifts the profile toward younger cells. That is a laboratory-level biological indicator, not a clinical statement.

Evidence on Skin and Wound Healing

Studies on cosmetic preparations containing GHK-Cu have been available since the 1990s. The evidence base for skin is among the better ones in the peptide field but remains limited to a few small studies.

Clinical Studies on Skin

Leyden et al. 2002 examined a GHK-Cu facial serum in 41 women over 12 weeks. Fine wrinkles, skin thickness on ultrasound and firmness by cutometer were measured.

Finkley et al. 2005 compared a GHK-Cu cream with placebo in 67 women over 12 weeks. Wrinkle depth, skin roughness and collagen density were assessed.

Wound healing: Wound dressings containing GHK are approved in the US for specific indications. For diabetic and venous ulcers there are studies on healing rate; the data are limited.

What results can be expected in an individual case cannot be derived from these studies. Questions about skin changes and wound healing belong in medical, and in particular dermatological, assessment.

Topical vs. Injectable Forms

A factual comparison of the two forms.

The evidence base thus differs markedly: limited human data exist for skin, none for systemic effects.

Injectable Forms: Classification and Risks

Injection of GHK-Cu is discussed in internet forums but is not approved and barely studied clinically. Randomized controlled trials in humans do not exist. Presumed effects derive from animal data, for example on hair, wound healing and general regeneration. Lab2go gives no usage guidance on this.

Risks of Systemic Supply

• Copper excess: GHK-Cu adds copper. With prolonged supply, serum copper and ceruloplasmin can rise. Wilson’s disease (copper storage disorder) is an absolute contraindication.
• Angiogenesis with tumors: Promoting new vessel formation is theoretically problematic with undiagnosed cancers.
• Injection risks: Non-sterile technique leads to local infections and abscesses.
• Purity: Research chemicals are not subject to pharmaceutical quality control. Identity and purity are not guaranteed.

These risks are one reason why related questions must be clarified exclusively with a doctor.

Lab Values from a Medical Perspective

In connection with copper and the liver, physicians typically look at these values:

• Serum copper (reference: 70 to 140 µg/dl)
• Ceruloplasmin (20 to 60 mg/dl)
• Liver values: ALT, AST, GGT. Basics in the liver values guide.
• Complete blood count
• Tumor screening by age and risk profile, where medically indicated

Single values are influenced by measurement method, time of day and inflammation. Above all the trend over time is informative, and the treating physician interprets it. Methodology in the blood values guide.

Hair and Scalp

GHK-Cu has also been studied in connection with hair growth since the 1990s. The evidence is weaker than for skin.

Animal studies in mice report enlarged hair follicles, longer growth phase (anagen) and denser hair under topical GHK-Cu lotion. Individual human observations point in the same direction. Large randomized trials are lacking, and a proven benefit for androgenetic alopecia does not exist. Hair loss has many causes and is assessed medically.

Interactions and Incompatibilities

The literature on cosmetic preparations describes some chemical sensitivities that matter for classification:

• Acids and oxidizing agents: The copper complex is considered sensitive to low pH and oxidation. High-concentration L-ascorbic acid and AHA/BHA acids such as glycolic and salicylic acid are mentioned.
• Light and oxygen: Copper peptides are considered light- and oxygen-sensitive, which matters for the shelf life and quality of a preparation.
• Systemic: Interactions with medication and existing conditions (such as copper metabolism disorders) have not been systematically studied.

Anyone wanting to clarify interactions with medication or other substances should speak with a doctor or pharmacist. For a clean starting point before any change in supplements or skin care, the supplement beginners guide gives a general overview.

Regulatory Status

EU and Germany

• Cosmetics: Regulated by the EU Cosmetics Regulation.
• Injectable forms: Not approved as drugs. Sold as research chemicals with “not for human consumption” label. Human use falls under drug law.
• Pharmacy compounding: Not permitted for GHK-Cu injections.

USA

• Cosmetics: Marketed as cosmetics.
• Wound dressings with GHK: FDA-cleared for specific indications (chronic wounds).
• Injectable forms: Not approved as drugs, research chemical status.

WADA (competitive sport)

GHK-Cu is not explicitly on the WADA prohibited list. Its classification for competitive athletes is unclear; questions are for the governing body and the anti-doping agency.

Positioning Against Other Peptides

A broader introduction to the peptide landscape is in the peptides beginners guide. Comparable peptides are classified informatively in the BPC-157 guide and the thymosin alpha-1 guide.

Questions for the Medical Consultation

Anyone interested in the topic can discuss the following points with a doctor:

1. Which goals and complaints are involved? Skin changes, scars or hair loss often have causes that an examination can clarify.
2. Which pre-existing conditions and medication apply? For example copper metabolism disorders, a history of tumors, pregnancy.
3. Which lab values are available? Copper, ceruloplasmin, liver, blood count as a baseline.
4. Which approved alternatives with an evidence base exist? The treating physician knows indications and risks case by case.
5. What is the legal situation? Human use of unapproved substances is subject to drug law.

For documenting biomarkers over time, the Lab2go features provide structure. The pricing overview shows the tariff options.

Conclusion: Limited Topical Data, Hardly Any Systemic Data

GHK-Cu is an endogenous peptide with two very different evidence situations. For cosmetic preparations on the skin there are small studies, for hair the data are weaker. For systemic injection there is hardly any human data, no approval and regulatory problems.

Three takeaways:

1. Skin evidence: A few small studies over 12 weeks. They allow no statement for an individual case.
2. Endogenous concentration: It drops with age, from about 200 ng/ml at 20 to about 80 ng/ml at 60. Whether a benefit of external supply follows is open.
3. Injectable forms: Not approved, copper risk, angiogenesis concerns with tumors. No recommendation for use; medical assessment is required.

This article does not replace medical advice and is not a recommendation for use. Intake, dose and therapy should be clarified with a doctor. Injectable forms of GHK-Cu are not approved as drugs; human use is legally problematic. Self-medication with unapproved substances can cause health and legal risks.